- Home
- STTK vs ROOT Comparison
STTK vs ROOT Comparison
Compare STTK & ROOT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | STTK | ROOT |
|---|---|---|
| Founded | 2016 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Property-Casualty Insurers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 792.9M | 889.5M |
| IPO Year | 2020 | 2020 |
Fundamental Metrics
Financial Performance| Metric | STTK | ROOT |
|---|---|---|
| Price | $6.85 | $56.30 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 7 | 5 |
| Target Price | $10.00 | ★ $92.40 |
| AVG Volume (30 Days) | ★ 773.5K | 254.4K |
| Earning Date | 05-01-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 53.02 | 28.96 |
| EPS | N/A | ★ 3.58 |
| Revenue | $1,000,000.00 | ★ $1,517,100,000.00 |
| Revenue This Year | N/A | $11.73 |
| Revenue Next Year | N/A | $12.80 |
| P/E Ratio | ★ N/A | $15.54 |
| Revenue Growth | N/A | ★ 28.95 |
| 52 Week Low | $1.59 | $40.91 |
| 52 Week High | $8.33 | $104.47 |
Technical Indicators
Market Signals| Indicator | STTK | ROOT |
|---|---|---|
| Relative Strength Index (RSI) | 44.39 | 50.25 |
| Support Level | $5.87 | $55.53 |
| Resistance Level | $7.75 | $59.77 |
| Average True Range (ATR) | 0.34 | 2.48 |
| MACD | -0.12 | 0.20 |
| Stochastic Oscillator | 11.51 | 67.01 |
Price Performance
Historical ComparisonAbout STTK Shattuck Labs Inc.
Shattuck Labs Inc is a biotechnology company specializing in the development of potential treatments for inflammatory and immune-mediated diseases. It is developing a potentially first-in-class antibody for the treatment of inflammatory bowel disease (IBD) and other inflammatory and immune-mediated diseases. The company's expertise in protein engineering and the development of novel tumor necrosis factor (TNF) receptor therapeutics comes together in its main program, SL-325, which has the potential to be a first-in-class death receptor 3 (DR3) antagonist antibody. In addition, the company is developing SL-425, a half-life extended version of SL-325, and multiple other preclinical DR3-based bispecific antibodies, for the treatment of patients with IBD.
About ROOT Root Inc.
Root Inc develops and launches a direct-to-consumer personal automobile insurance and mobile technology company. It generates revenue from the sales of auto insurance policies within the United States.